Celldex Therapeutics (CLDX) Non-Current Assets (2010 - 2026)

Celldex Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $52.0 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 13.82% year-over-year to $52.0 million in Q1 2026; TTM through Mar 2026 was $188.5 million, a 11.61% increase from a year earlier, with the FY2025 full-year figure at $48.3 million, up 6.95% from the prior year.
• Non-Current Assets grew to $52.0 million in Q1 2026 per CLDX's latest filing, from $48.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $52.0 million in Q1 2026 and bottomed at $33.3 million in Q1 2022.
• The 5-year median for Non-Current Assets is $35.0 million (2022), against an average of $39.2 million.
• Across the five-year window, Non-Current Assets dropped 11.24% in 2022 and jumped 36.37% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $35.0 million in 2022, then dropped by 3.16% to $33.9 million in 2023, then jumped by 33.14% to $45.2 million in 2024, then climbed by 6.95% to $48.3 million in 2025, then advanced by 7.68% to $52.0 million in 2026.
• Per Business Quant, the three latest CLDX Non-Current Assets figures stand at $52.0 million (Q1 2026), $48.3 million (Q4 2025), and $44.1 million (Q3 2025).